NASDAQ:CFRX
Delisted
ContraFect Corporation Stock News
$0.0500
+0 (+0%)
At Close: Mar 04, 2024
El Granada tira de carácter para sacar su billete definitivo a Europa
07:31pm, Thursday, 01'st Oct 2020El Granada tira de carácter para sacar su billete definitivo a Europa
07:31pm, Thursday, 01'st Oct 2020Carbios to Move Facilities to a Michelin Site in Clermont-Ferrand, France
12:00am, Monday, 28'th Sep 2020
Carbios to move facilities to a Michelin site in Clermont-Ferrand, France
El Granada sigue adelante y le espera el Malmoe en el playoff
08:49pm, Thursday, 24'th Sep 2020El Granada sigue adelante y le espera el Malmoe en el playoff
08:49pm, Thursday, 24'th Sep 2020CFRX: Enrollment Continues in Phase 3 Trial of Exebacase…
09:50am, Wednesday, 19'th Aug 2020
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect announced the first patient had been dosed in the Phase
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update
11:30am, Friday, 14'th Aug 2020
Exebacase Phase 2 study results published in the Journal of Clinical Investigation Continued patient enrollment in ongoing Phase 3 DISRUPT study of exebacaseSuccessful public equity offering, private
YONKERS, N.Y., July 20, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.
How Much Are ContraFect Corporation (NASDAQ:CFRX) Insiders Spending On Buying Shares?
12:48pm, Friday, 03'rd Jul 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
2 “Strong Buy” Small-Cap Stocks That Could See Outsized Gains
02:56pm, Thursday, 18'th Jun 2020
As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P; 500 and Dow Jones followi
